Overview

Protocol for Women at Increased Risk of Developing Breast Cancer

Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
To assess the effects of twelve months of celecoxib administration by evaluating breast tissue needle aspirations, to determine if cell growth can be slowed.
Phase:
Phase 2
Details
Lead Sponsor:
Carol Fabian, MD
Collaborator:
Susan G. Komen Breast Cancer Foundation
Treatments:
Celecoxib